Atlas Bio — Computational platforms for gene therapy and clinical intelligence

The funnel shift

Let our AI Intelligence Engine carry 80% of the journey for your cure to the patient.

The search for a cure — capsid, target, trial design, treatment pathway — burns the most resources at the broadest part of the funnel, where the most candidates fail. Atlas Bio's platform takes that broad search and runs it through a calibrated, audit-traceable engine. Your team owns the high-confidence 20% — the candidates the platform has named, ranked, and justified — not the whole space.

Stage 01 · Engine handles

10⁴–10⁹

Broad candidate space

Every variant, target, trial design, or treatment pathway in the addressable evidence base. Where conventional pipelines burn time and capital.

Stage 02 · Engine produces

~80%

Search compressed

Calibrated ranking, translation-trap detection, evidence-source audit trail. Per-candidate uncertainty bounds, named contributing factors, documented limitations.

Stage 03 · Team commits

~20%

High-confidence shortlist

Your SMEs and wet-lab teams focus the expensive verification cycles where the platform has named the highest-confidence candidates and surfaced the failure modes.

What the platform handles · ~80%

Broad search, audit-traceable

Evidence aggregation across heterogeneous sources
Calibrated ranking with credible intervals
Translation-trap detection (the LY6A pattern, the mouse-to-NHP gap)
Per-candidate failure-mode flagging
Continuous learning as partner data flows back

What your team handles · ~20%

Final commitment, expensive verification

Wet-lab execution on shortlisted candidates
NHP cohort design and biodistribution studies
Clinical trial commitment and operational rollout
Final go / no-go decisions under SME judgment
Domain-specific interpretation of platform outputs

The leverage shift. The 80% the platform handles is the volume work — broad, repetitive, evidence-aggregating, low cost per candidate. The 20% your team handles is the irreplaceable judgment work — expensive per candidate, but now applied where it counts. The funnel doesn't replace your team. It changes the leverage ratio.

Need a defensible answer in a hard population?

Briefings are 30 minutes. Bring a regimen, an indication, or a capsid spec; we walk through how the framework would model it. Verified clinicians and sponsors unlock the manuscript bundle.